Shockwave Medical (BMV:SWAV *) - Aandelenkoers, Nieuws & Analyse

SWAV * Overzicht aandelen

A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. Meer informatie

SWAV * fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	3/6
Prestaties in het verleden	4/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 8.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 13.48% per jaar groeien

De winst groeide het afgelopen jaar met 177.1%

Risicoanalyse

Hoog niveau van niet-contante inkomsten

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

Shockwave Medical, Inc. Concurrenten

Inspire Medical Systems

NYSE:INSP

US$5.5b

TransMedics Group

NasdaqGM:TMDX

US$2.6b

APT Medical

SHSE:688617

CN¥35.4b

Globus Medical

NYSE:GMED

US$11.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Shockwave Medical
Historische aandelenkoersen
Huidige aandelenkoers	US$3,700.00
52 Week Hoogtepunt	US$5,111.53
52 Week Laag	US$3,700.00
Bèta	1.01
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	-23.40%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-16.56%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	SWAV *	MX Medical Equipment	MX Markt
7D	0%	0%	0%
1Y	-23.4%	0%	0%

Rendement versus industrie: SWAV * presteerde slechter dan de MX Medical Equipment -sector, die het afgelopen jaar een rendement van 14.8 % opleverde.

Rendement versus markt: SWAV * presteerde slechter dan MX Market, dat het afgelopen jaar een rendement van -4 % opleverde.

Prijsvolatiliteit

Is SWAV *'s price volatile compared to industry and market?
SWAV * volatility
SWAV * Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: SWAV * heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van SWAV * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	1,001	Doug Godshall	shockwavemedical.com

Shockwave Medical, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Shockwave Medical zich tot de beurswaarde?
SWAV * fundamentele statistieken
Marktkapitalisatie	Mex$110.74b
Inkomsten(TTM)	Mex$4.17b
Inkomsten(TTM)	Mex$11.49b

26.5x

Koers/Winstverhouding

9.6x

P/S-verhouding

Is SWAV * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SWAV * resultatenrekening (TTM)
Inkomsten	US$671.28m
Kosten van inkomsten	US$87.57m
Brutowinst	US$583.70m
Overige uitgaven	US$339.82m
Inkomsten	US$243.88m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	6.61
Brutomarge	86.95%
Nettowinstmarge	36.33%
Schuld/Eigen Vermogen Verhouding	121.6%

Hoe presteerde SWAV * op de lange termijn?

Bekijk historische prestaties en vergelijking

SWAV * Overzicht aandelen

Beloningen

Risicoanalyse

Shockwave Medical, Inc. Concurrenten

NYSE:INSP

US$5.5b

NasdaqGM:TMDX

US$2.6b

SHSE:688617

CN¥35.4b

NYSE:GMED

US$11.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Recent updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Chief Accounting Officer recently sold Mex$22m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022

ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022

Independent Director recently sold Mex$7.9m worth of stock

Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance

Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL

Key Executive recently sold Mex$17m worth of stock

Key Executive recently sold Mex$17m worth of stock

ShockWave Medical, Inc. Announces Executive Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ShockWave Medical, Inc. Provides Revenue Guidance for the Full Year 2022

ShockWave Medical, Inc. Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions